The SGLT(“sodium glucose-linked transporter”)-2 inhibitors have demonstrated cardioprotective effects in addition to antidiabetic effects. The current evidence supports the benefit of several agents of SGLT-2-i in the treatment of heart failure in both patients with and without diabetes. More recently, evidence of efficacy of HFrEF has been extended to HFmrEF and HFpEF.
This content is machine-translated. Please contact us if you need professional translation services.
Publikation
- HAUSARZT PRAXIS
